Pertussis acellular vaccine - BioNet-Asia

Drug Profile

Pertussis acellular vaccine - BioNet-Asia

Alternative Names: Pertagen; rPT vaccine; Viaskin® rPT; Viaskin®-PT

Latest Information Update: 19 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioNet-Asia; Mahidol University
  • Developer BioNet-Asia; DBV Technologies; University of Geneva
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Registered Pertussis

Most Recent Events

  • 15 Jun 2018 BioNet-Asia plans a phase II trial for Pertussis (Prevention) in Thailand , (TCTR20180321004)
  • 09 Mar 2017 BioNet Asia in collaboration with the University of Geneva completes the PertADO trial in Pertussis (Prevention) in Switzerland (NCT02946190)
  • 23 Dec 2016 Registered for Pertussis (Prevention) in Thailand (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top